Cardiovascular
Improvement in Beta-Cell Function Observed After Three Years of BYETTA(R) Therapy: Data Presented at ADA 2010
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26, 2010 /- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN ) and Eli Lilly and Company (NYSE: LLY ) today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on...
New Data Demonstrates Victoza® (liraglutide rDNA injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52...
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26 /- Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza® in combination with metformin produced sustained and...
Boehringer Ingelheim Announces Pivotal Phase III Data Showing Linagliptin Reduced Blood Sugar Compared to Placebo in People With Type 2 Diabetes
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26 /- Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c (HbA1c),(1-4) fasting plasma glucose (FPG)(1-4) and postprandial glucose...
Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
June 26, 2010 9:36 am | by Bio-Medicine.Org | News | CommentsORLANDO, Fla. , June 26 /- An estimated 75 percent of adults with type 1 and type 2 diabetes say they believe they know what their blood sugar levels are without testing, according to data presented at the American Diabetes Association (ADA) 70th Scientific Sessions. These results are...
HeartWare names Larkin as board chairman
June 25, 2010 7:35 am | by Mass High Tech: The Journal of New England Technology | News | CommentsHeartWare International Inc., a Framingham maker of heart devices, has appointed board member C. Raymond Larkin, Jr. to the role of chairman of the board.
Phase 1 trial triggers $1M payment for ImmunoGen
June 25, 2010 5:34 am | by Mass High Tech: The Journal of New England Technology | News | CommentsBiotech firm ImmunoGen Inc. is in line for a $1 million milestone payment from sanofi-aventis, now that sanofi has launched a Phase 1 clinical trial of ImmunoGen's SAR650984 investigational antibody.
Alnylam's Maraganore joins Agios board
June 24, 2010 10:36 am | by Mass High Tech: The Journal of New England Technology | News | CommentsAgios Pharmaceuticals Inc., a Cambridge biopharmaceutical focused on the field of cancer metabolism, has named John Maraganore, CEO of Alnylam Pharmaceuticals, to its board of directors.
Attenda underpins the infrastructure for Microsoft HealthVault UK launch
June 23, 2010 1:33 am | by RealWire | News | CommentsLondon - June 23, 2010 - Attenda Limited, the Always On Managed Services company, today announced that it had reached an agreement with Microsoft for support in the UK of Microsoft HealthVault, a privacy and security-enhanced, cloud-based platform that enables individuals to store, share...
Walmart, Lilly Team Up to Provide Human Insulin to People With Diabetes
June 22, 2010 6:35 am | by Bio-Medicine.Org | News | CommentsINDIANAPOLIS and BENTONVILLE, Ark. , June 22 /- Walmart (NYSE: WMT ) and Eli Lilly and Company (NYSE: LLY ) announced today they're teaming up to provide an affordable insulin option for people with diabetes. Beginning in mid-September, Lilly's Humulin ® brand of insulin will...
Cardiogenesis (CGCP) Listing Upgraded to New OTCQB(TM) Market for All U.S. Registered and Reporting OTC Securities
June 22, 2010 6:34 am | by Bio-Medicine.Org | News | CommentsIRVINE, Calif. , June 22 /- Cardiogenesis Corporation (OTCQB: CGCP) today announced that its shares are now being quoted on the newly launched OTCQB™ market. Launched in April 2010 , the OTCQB is a new market tier for OTC-traded U.S. companies that are registered and reporting with...
MedGadget's MedTech Monday: Custom-fit degradable cranial implant
June 21, 2010 8:35 am | by Mass Device | News | CommentsA custom-fit degradable implant for filling bone defects after craniofacial surgery; a study shows Bard's LifeStent as superior to stentless angioplasty; Micrus' DeltaPAQ and DeltaPlush microcoils cleared in Japan; and CorMatrix's cardiac tissue repair wins CE Mark. ...
Cardiovascular Devices Market Outlook June Update by ReportsandReports
June 21, 2010 4:37 am | by Bio-Medicine.Org | News | CommentsDALLAS , June 21, 2010 /- ReportsandReports announces it Will Carry Cardiovascular Devices Market Outlook 2016 June reports in its store. Netherlands Cardiovascular Devices Market Outlook to 2016 ( http://www.reportsandreports.com/market-reports/netherlands-cardiovascul......
California Cryobank Welcomes New Director of Quality/Regulatory Affairs
June 21, 2010 4:37 am | by Bio-Medicine.Org | News | CommentsLOS ANGELES , June 21 /- California Cryobank (CCB), a worldwide leader in biotechnology services, is proud to announce the recent hiring of Rama Tyagi as the company's Director of Quality/Regulatory Affairs. Tyagi's hiring into the newly created position echoes CCB's ongoing commitment to...
Boston Scientific Expands PolarCath® Peripheral Dilatation System With New Balloon Sizes
June 21, 2010 4:36 am | by Boston Scientific | News | CommentsLonger balloons provide physicians more options for treating peripheral artery disease
Medco and Celesio Announce Pan-European Joint Venture to Enhance Quality of Clinical Care and Reduce Overall Healthcare Costs
June 21, 2010 1:34 am | by Bio-Medicine.Org | News | CommentsBERLIN , June 21 /- Medco Health Solutions, Inc. (NYSE: MHS ) and Celesio AG, two of the world's leading pharmacy-driven healthcare companies, today announced a joint venture with a long-term goal of improving patient health and helping to relieve the crushing financial burden on...
Zydus' Novel Orally Administered GLP-1 Agonist - 'ZYOG1' to treat Diabetes and Obesity Enters Phase I Clinical Trial
June 20, 2010 10:34 pm | by Bio-Medicine.Org | News | CommentsAHMEDABAD, India , June 21, 2010 /- Zydus Cadila, a global healthcare provider and one of India's leading healthcare companies has received Phase I clinical trial permission from the DCGI for ZYOG1 - a novel GLP-1 agonist. Designed and developed at the Zydus Research Centre using a unique...
Drug Targets Lupus by Tricking Immune System
June 20, 2010 8:35 pm | by Massachusetts Institute of Technology | News | CommentsA new approach shows early promise in fighting the devastating disease.
St. Jude Medical wins another CE Mark for cardiac ablation device
June 18, 2010 8:35 am | by Mass Device | News | CommentsSt. Jude Medical Inc. won another CE Mark from the European Union for a cardiac ablation device, this time for its cryogenic Therapy Cool Flex catheter. By Brandon Glenn St. Jude Medical Inc. (NYSE:STJ) won CE Mark approval in the European Union for a cryogenic cardiac ablation...
Zoll wins three-year AED contract in U.K.
June 18, 2010 8:35 am | by Mass Device | News | CommentsZoll Medical Corp. wins a three-year contract with Britain's national heart charity, the British Heart Foundation, to be its exclusive supplier of automated external defibrillators. Zoll Medical Corp. (NSDQ:ZOLL) landed a lucrative deal as the British Heart Foundation's...
MADIT-CRT Trial Data Show Women Received Greater Benefit From CRT-Ds Than Men
June 18, 2010 4:34 am | by Boston Scientific | News | CommentsNATICK, Mass. and NICE, France, June 18 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical
NMT Medical dives on Closure I trial failure
June 17, 2010 12:36 pm | by Mass Device | News | CommentsNMT Medical Inc.'s Closure I trial fails to meet its primary endpoint, sending its stock down nearly 75 percent in late-day trading. A clinical trial of NMT Medical Inc.'s (NSDQ:NMTI) flagship StarFlex device failed to meet its primary endpoint, sending the company's stock...
FDA slaps U.S. Red Cross with $16 million in fines over blood safety violations
June 17, 2010 12:36 pm | by Mass Device | News | CommentsThe Food & Drug Administration fines the American Red Cross $16 million over the collection and manufacture of blood products. The Food & Drug Administration fined the American Red Cross $16 million for failing to meet federal rules about the collection and manufacture...
Adding Greater Precision to Cardiac Ablation
June 17, 2010 11:45 am | by Bob Allison | Articles | CommentsCardiac ablation is used extensively for treating cardiac arrhythmia, but has been hindered by the lack of an adequate feedback mechanism for determining tissue temperature during ablation. This article describes a system based on microwave sensing technology that allows both heating at RF or microwave frequencie
Medtronic launches new ICD line in Europe
June 17, 2010 10:34 am | by Mass Device | News | CommentsMedtronic Inc. launches its Protecta line of implantable cardiac defibrillators in Europe. By Brandon Glenn Medtronic Inc. (NYSE:MDT) launched a line of implantable cardioverter defibrillators in Europe. The company’s Protecta ICDs and cardiac resynchronization therapy...
St. Jude says catheter technology gets EU approval
June 17, 2010 6:45 am | by The Associated Press | News | CommentsSt. Jude Medical Inc. said Thursday European Union regulators approved its Ensite Contact technology, which is designed to improve procedures used in treatment of a serious heart condition.St. Jude said Ensite Contact is a diagnostic system of ablation catheters, hardware and software that can...
